罗沙司他治疗非髓系恶性肿瘤化疗患者贫血的疗效与安全性:一项随机、开放标签、阳性对照III期研究
这项在中国44个中心开展的开放标签、非劣效性III期研究纳入159例接受多周期化疗的非髓系恶性肿瘤合并化疗相关贫血(CIA)患者,随机(1:1)接受口服罗沙司他或皮下注射重组人促红素-α治疗12周。主要终点为基线至第9-13周平均血红蛋白(Hb)浓度变化的最小二乘均值(LSM),罗沙司他为17.1 g/L,rHuEPO-α为15.4 g/L,组间差异为1.7 g/L(95%CI -3.39至6.84),单侧97.5%CI下限为-3.4 g/L,高于预设非劣效界值-6.6 g/L,确立非劣效性。罗沙司他在治疗CIA方面非劣效于rHuEPO-α,口服剂型可能提高依从性。
要点
- 罗沙司他组Hb从基线至第9-13周LSM变化为17.1 g/L,rHuEPO-α组为15.4 g/L,组间差异1.7 g/L(95%CI -3.39至6.84)。
- 单侧97.5%CI下限-3.4 g/L高于非劣效界值-6.6 g/L,罗沙司他非劣效于rHuEPO-α。
- 6个关键次要终点中5个支持非劣效性,不良事件发生率两组大致相当。
核心结论
- 在接收多周期骨髓抑制化疗的非髓系恶性肿瘤患者中,罗沙司他治疗化疗相关贫血非劣效于rHuEPO-α。
- 罗沙司他的口服剂型可能潜在提高依从性。
研究设计与样本
- 开放标签、非劣效性III期研究,在中国44个中心开展。
- 纳入159例年龄≥18岁、非髓系恶性肿瘤合并化疗相关贫血的参与者,随机(1:1)分配至口服罗沙司他组或皮下注射rHuEPO-α组,每周三次,治疗12周。
- 罗沙司他起始剂量按体重分别为100 mg(40-<50 kg)、120 mg(50-60 kg)和150 mg(>60 kg),每周三次;rHuEPO-α起始剂量为150 IU/kg,每周三次;两者剂量均可调整。
- 主要终点为基线至第9-13周平均血红蛋白浓度变化的最小二乘均值(LSM)。
- 符合方案集共140例(罗沙司他组78例,rHuEPO-α组62例)。
主要发现
- 罗沙司他组Hb从基线至第9-13周LSM变化为17.1 g/L(95%双侧CI 13.58至20.71),rHuEPO-α组为15.4 g/L(95%双侧CI 11.34至19.50),组间平均差异为1.7 g/L(95%CI -3.39至6.84)。
- 治疗差异的单侧97.5%CI下限为-3.4 g/L,高于预设非劣效界值-6.6 g/L,确立非劣效性。
- 6个关键次要终点中5个支持非劣效性。
- 两组不良事件发生率大致相当,与既往研究结果一致。
关键数值与推荐
- 非劣效界值为-6.6 g/L;治疗差异单侧97.5%CI下限-3.4 g/L大于该界值,判定非劣效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the efficacy and safety of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor, for chemotherapy-induced anemia (CIA) in patients with nonmyeloid malignancies receiving multicycle treatments of chemotherapy. PATIENTS AND METHODS: In this open-label, noninferiority phase III study conducted at 44 sites in China, 159 participants age ≥18 years with CIA nonmyeloid malignancy and CIA were randomly assigned (1:1) to oral roxadustat or subcutaneous recombinant human erythropoietin-α (rHuEPO-α) three times a week for 12 weeks. Roxadustat starting dosages were 100, 120, and 150 mg three times a week for participants weighing 40-<50, 50-60, and >60 kg, respectively. rHuEPO-α starting dosage for all participants was 150 IU/kg three times a week. Both roxadustat and rHuEPO-α dosages could be modified. The primary end point was least-squares mean (LSM) change in hemoglobin (Hb) concentration from baseline to the concentration averaged over weeks 9-13. RESULTS: Of the 159 participants randomly assigned, 140 were included in the per-protocol set (roxadustat, n = 78; rHuEPO-α, n = 62). The LSM (95% two-sided CI) change from baseline to weeks 9-13 in Hb concentration was 17.1 (13.58 to 20.71) g/L with roxadustat and 15.4 (11.34 to 19.50) g/L with rHuEPO-α (mean difference [95% CI], 1.7 [-3.39 to 6.84]). The lower bound of the one-sided 97.5% CI for the treatment difference (‒3.4 g/L) was greater than the predefined noninferiority margin of ‒6.6 g/L, establishing noninferiority. Noninferiority was supported by five of six key secondary end points. Rates of adverse events were generally comparable between treatments and consistent with previous findings. CONCLUSION: Roxadustat was noninferior to rHuEPO-α in treating CIA in participants with nonmyeloid malignancies receiving multicycle treatments of myelosuppressive chemotherapy. The oral formulation of roxadustat may potentially increase compliance.
引用
- Lu S, Wu J, Jiang J, et al. Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study. J Clin Oncol. 2024. PMID: 39353163. doi:10.1200/JCO.23.02742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。